BioCryst Pharmaceuticals (BCRX) 3 Aug 232023 Q2 Earnings call transcript

Company Profile

Participants

John Bluth	Investor Relations
Jon Stonehouse	Chief Executive Officer
Anthony Doyle	Chief Financial Officer
Charlie Gayer	Chief Commercial Officer
Helen Thackray	Chief R&D Officer
Tazeen Ahmad	Bank of America
Stacy Ku	Cowen & Co.
Jon Wolleben	JMP Securities
Justin Kim	Oppenheimer & Co. Inc.
Serge Belanger	Needham & Company

Call transcript

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the BioCryst Second Quarter 2023 Earnings Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference to Mr. John Bluth at BioCryst. Please go ahead.

John Bluth

much. very you Thank welcome results second conference and update XXXX and financial call. to morning quarter BioCryst's corporate Good Today’s press release our website. and accompanying slides are available on Doyle; Participating Stonehouse; Gayer; are today Chief Chief Anthony and Dr. with Charlie Commercial Officer, CEO, R&D Officer, me CFO, Jon Thackray. Helen

will we questions. your remarks, our answer Following

unknown statements, and company’s Before begin, forward-looking These as as the forward-looking financial performance that statements and actual presentation. known expressed to and/or regarding and achievements uncertainties, statements be call our subject are in will today’s from performance information we those cause conference may future future achievements. risks results note contain please results, including to this results, which or implied unaudited well or or performance any materially different future

on statements. reliance these You forward-looking should place not undue

including our our Commission, For to the a please refer filed of on company’s Exchange Securities and detailed accessed factors, website. discussion the be risk documents with can additional which information,

today's conference includes addition, financial pro-forma non-GAAP, In call measures.

these the section of earnings Relations non-GAAP in release press press For the a at biochrist.com. the website measures release to comparable reconciliation most GAAP our measure, refer against of posted please financial directly Investor

over I’d Stonehouse. the now call to like turn to Jon

Jon Stonehouse

treatment and still market, second ORLADEYO. $X that where year steady in is The success $XXX by the will in in in John. rare have step-up achieve and less are in great the team but to team. to want many his had entire treatment, for Charlie no I to point positions expected peak. more on Charlie at switching ORLADEYO revenue options and out yet growth than the of patients million the and share revenue That details, strong achieved and patients the a the we execution Thanks, they're for there commercial continue see of quarter consistent we million to us well

HAEA patients recently approval Orlando, the before was major since in US the also Florida. US XXXX, HAEA of and first Charlie gathering attended was This of which I the ORLADEYO. Patient Summit

attendance HAE us our and was X,XXX this record in for and an of families event company launching was a major were community. connections Patient showcase pad fantastic a it Our and for strategy make this our with amazing patients opportunity and is activation part that. their to

we're we're pipeline. Lastly the excited about with progress our very making

We November at to will labs plan more Birmingham, We show about an host additional you previously. R&D much day programs and XX on our assets haven't Alabama. discussed we in

one diseases November. market across inherent disease medicines clearly on of ORLADEYO. our hope multiple with patients is in platform at them sharing probability rare see to to more We more for least design drug to Our the you allows with get structure-based drug or programs, first-in-class to how targets us you spread will best-in-class focused discovery pursuing the of risk follow and the of our forward increases success and look to

it Charlie. hand to I'll over Now,

Charlie Gayer

John. Thanks,

for quarter I'll out on expected. rolled first reauthorization the continued Second and therapy jumped linear prescription provide quarter following ORLADEYO growth The both. in results on long-term process. color patients more revenue as we

same U.S. the added X,XXX continued at over same pace treated in I about earnings to the patients consistent quarter. States number a had patients the again past we second strong of Growth in crossed therapy the years. that United a on added we in seen noted call the therapy, patients last quarter net at two patients in the with for ORLADEYO the After we've first

growth would now. above we you like. what is total looks are This expect, As that linear

to adding progress getting great QX last in paid of the most since patients made We paid in a also patients net therapy, quarter year.

ago. year paid as exact a the added number In net same patients fact, of we

is significantly number year, We current also even though our the patient had similar discontinuations quarter second last of a pace very in as larger.

linear again, growth. the So down discontinuation to continues rate go

patient to example, a As XX% over year continued we just heavy on during to The in jump it was were the our forecasted, and like our also reauthorization QX revenue patients the for but to we biggest growth substantial driver a took period. That ago. roughly ability pace, QX, did therapy. are free end in March. product paid February, of XX% In get January fell of about by the improving patients

product of of patients the QX, By to XX%. end the fell percentage on free

we Every move So point we progress more patient pace completed. made annual current therapy million reauthorizations were worth revenue. our about in is percentage $X to a after lot paid of that

improvements So meaningful. these are very

see that team to on Based is over our continued in the next the work we improvements the years. in doing, percentage trends expect steady see we few

we confident U.S. pay our status. goal to patients will on over are of of ORLADEYO long-term getting reach We XX%

bottom line this. is the The U.S. in

growing at rate We on we consistent patients better quarter, as paid every launch. we therapy at just done are a patients have are even moving therapy. total very And getting since to

patient steady less For reach global for of track no year. to we in revenue million $XXX growth the the rest XXXX, than along revenue to with expect

being In on you revenue future seasonality, we in sales, growth and the based the in The are can of and and the QX of world. same QX doing years, U.S. currently XX% insurance QX. QX larger accounts about global but this and overshadow down how on based growth rest in bump may slightly revenue steady trends for well reauthorizations, Europe pattern expect patient being a

now quarterly Europe seeing steady we in is therapy. on in growth What very to similar right U.S., patients are the

the for markets around launch groundwork countries the in global trajectories coming and the growth U.S. XX% more patient laying way as more similar peak world, we on to of the from are beyond We sales

we earlier, the members. HAEA an us world. there for family and same interest As how much demand along prophylaxis their one-daily thing the We're attended is Their and Orlando therapy. patients enthusiasm around Jon with in X,XXX showed Summit oral, seeing the U.S. said recently

Our teams Europe, Middle phenomenal need and ORLADEYO partners our who America, are North doing bring and work America patients the East Latin in to to it.

therapy still am they improving. to the world. proud living I over keep teams patients of all we with HAE transformative and our bringing growing and how this global keep We are

I'll it over Helen, to turn you?

Helen Thackray

It injectable the to difficult hear therapy why APeX-P of at on needs at Hello, patients and sites, are evaluation oral, exciting with is especially as note best meet including in the indication for new future HAE. from using multiple running to is a once-daily burden Charlie. expected. formulation am Thanks, children. children so the we That is to is pleased focused ORLADEYO trial, a proceeding and the was Summit. many granules with pediatric of that enrolment of APeX-P up I HAEA

the programs in pipeline, we to with that we haven't Day will to R&D where our seen before. molecules now November, Turning you you share looking are on new and forward details

which bring our first-in-class patients best-in-class to have bring a as with to we and is ORLADEYO. following molecules we to diseases goal with Our and pipeline more product to or with that, did market rare second

our criteria, we meet risk to As our focus our across additional in are Adding achieving by chances in and bringing goal diseases for and rare increases early patients. investments adding registrations products of that success our overall we molecules, then these development. that diversifying discovery multiple targets options to and options through

that are have until you've that more This to daily one faculty shows which R&D later we for invest than pivotal efficacy accelerate we options we other in decisions program inhibitor BCXXXXXX clear good have see We proportionately expensive. a that to As disciplined patients. molecule. with an about our BCXXXXXX. first-in-class as likely spending with safety, best-in-class for data is are or or We won't the are approach stage is a products, is seen, and oral, dosing, excellent want data better to also

pivotal we this development. is profile, this has to have BCXXXXXX here, best-in-class we show, and a data trials and we stop market. molecule, best-in-class the the to data run the invest If molecule If show, of it the will bring profile don't will

plenty we there do still It BCXXXXXX two is of and have to but today. with share is with unknowns early, updates you program,

to multiple have in dosing another level. dose sending We volunteers in restarted dose add trial our healthy

up evaluated with XX we previously XX alternative at data milligrams, and control up of proceeding of hours single We also post-dose. have the support doses to pathway evaluation where milligrams, in to patients. doses durable excellent These XXX saw multiple

to the our more This we do model, PK pivotal dosing pivotal, and our a in volunteer daily inform PK eventually information take robust obtain XX data to to patients healthy for in milligrams XXX work final model Now, days. we for will at with set higher will is dose parallel dosing refine selection.

We are patients. ranging in trial, with dose BCXXXXXX now also proceeding our

to begin patients initial with by of expect enrolling end year the the year. We available next data

trial and clinical pivotal that conducting IgAN. We alternative PNH determine meets and this complement into if To in effective, a work forward move we outcomes. are like our dose safe, for activity to program mediated have criteria have renal, of chosen to a evaluation in in one-stale pathway diseases patients, both we

discovery in BCXXXXXX, as and advance Beyond continue for targets. pipeline invest build our we new early to we

and are pipeline we November progress now Center in BioCryst with share doing Birmingham, ready at of to in Discovery a molecules day look to exciting forward at Excellence this growing We the our Alabama. our R&D of

Now I Anthony. call turn the over to will

Anthony Doyle

ORLADEYO for revenue based to patient quarter the anticipated will we quarter. step underlying we and strong performance similar from in year's Helen. QX, the last $XX increase cadence, fourth that Thanks then anticipate that continuing up quarterly again revenue we saw coming in revenues QX, Global at million, growth third second the on the and in and

is revenue $XXX ORLADEYO million. at Year-to-date over

that or for revenue the $XX.X the next quarters in $XXX million second of million in we're the an confident our than half two over of we guidance year. will achieve revenue no approximately come expect and $XXX to We at million average less

to can earnings I'd like attention your financials quarter our a detailed to and release second call items. few You press find today's in

Day continue of XXXX of to second R&D $XX XX% of in including revenue, half for that trend for of trials from compensation XXXX, million QX sales than Of in non-cash remaining in first the the in factor million, and stock investment Helen and our be the the at pipeline from we revenue not reduced R&D we R&D of BCXXXXXX that came of discussed share million came $XX.X half additional with the from XXXX XXXX, significantly ex-US, that that investment November. US and expect over second the $XX.X same continued expenses, to in were that $XX million even respectively. for about and million, will quarter, ORLADEYO in more lower flat investment compared came increases and period we to QX Operating for half global of XX% the quarter at Total coming of XXXX the the will $X.X which $XX.X ORLADEYO. as XXXX

$XXX our April, year at guidance at into XXXX, out for proceeds Cash and the was million date greater debt at improved we quarter the refinancing $XX net $XXX.X of reiterate second We to includes the full million, year that flat OpEx million year. end prior to terms. the repayment that a from gave closed of deal capital in Pharmakon moved us our our that access

includes Net were per revenues. million operating per for pro-forma XXXX basis, following a quarter in Adjusting time at cash QX our million the approximately $XX GAAP $XX from for last of million extinguishment negative negative the debt impact charge of came for share an to charge this the the driven refi one earnings quarter quarter, $X.XX the Pharmakon. primarily improved increased on with utilization out that $X.XX, approximately, approximately $XX earnings share in by quarter.

$X strong we're prior continuing to no sales all flat advancing to we move position, as performance to forward. in invest towards combined to with company we of of our continuing shape as financial while the year, the pipeline, strong $XXX XXXX billion, value million of great than on less With move generate capital onwards in our our goal ORLADEYO, peak OpEx

back I'll pass to Now, it Jon.

Jon Stonehouse

you, Thank Anthony.

excited from webcast. XX so rest of our to we want execution, that you of our Alabama. R&D some QX in and labs great the very We pipeline and and a participate or Birmingham, whether advancing November Day the we employees direct is We've plan Birmingham got of you quarter, will report I on to for via at of it's to before earnings ORLADEYO the performance had great host thank a are BioCryst space, day the the limited able So to so the result that. be

a for of reason or the who what pretty are and on for why One, reasons. found main do asking in how be day capable is and there's there's hands and we college a appreciation Tuscaloosa two holding And LSU play may seeing the better what are you Alabama, and on scientists, have after we it in have of you you're Saturday you football when game doing. down meeting Some Friday do where next a second this road the those afternoon we our of fans is to there that coming important not, Alabama. we we're

So Birmingham, in we Day on to look forward hosting our November R&D XX Alabama.

now your up And open to We're it our for that's for questions. it remarks. going prepared

Operator

instructions] go from ahead. Ahmad America. with Bank Tazeen of Our first comes [Operator question Please

Tazeen Ahmad

I guys, bit get you're Hi on and about good half for wanted flight of the looking to maybe start a ORLADEYO how color trends. the Alabama. for I'll of to morning thinking second little a year

specific were third saying some see growth about you that expect Now, you quarter. and in to fourth the

your be What mature think going at which very in into And you I think is is where just from? you're growth upside marketing that fairly strong, how are for people team, into for do and need the outside launch? do would focus example, your be coming this real most unmet of now to could you areas turn where your see growth, knowing Thanks. your areas years. coming of

Charlie Gayer

take Sure. that. Tazeen, I can

of so patients pace the the second all, additions So therapy. first on up the to half revenue about at go year, this the expect of the of we question of

I've therapy, what's in to in and the as really drive we've QX done patients that's talked QX growth it's about, so So growth consistent had since launch. just going as on

as and would a once rather is is all injectable are that day and haven't your things the try being about tried who their disease to of pill far we of to so all taking patients opportunity, the as therapies, great a get patients other people ORLADEYO the treat what unmet the are majority prophylaxis with question unmet who HAE prophylaxis. know those yet need lot the need, equal, one And

number our benefit treating So try we're disease over as chance and with by oral more and focusing drug. much giving how on the them seeing keep switch priority to to they going an ORLADEYO can their

Jon Stonehouse

COVID one the things patient Charlie, at at that I'll of what in of summit going the aware and activation it that's add, patients Orlando, more think continued because patient when were had was we we available heard growth. approved we the for potential that was launch them. is, Tazeen, we from with a the were they first and to get And the that think time I I challenge

bottom But on. are drugs controlled line there good lot the is of that there's out people a

try for And it, to by way them to doctor to want so by it patient get being works yourself. if it's patient tackling better it's them, because injecting doctor, than it

Tazeen Ahmad

you $X goal? how you that. in have Okay, would for confidence to billion have in take Jon, it thanks now peak. sense you And, a reaching where are reiterated your that of Do long reach from

Anthony Doyle

$XXX this year. take to what think what year on say I we'll we -- this talking last when to you $X take we've you of sense can our said between again more about. million It'll expect on year So is of one before, give and million $XXX Tazeen, some about it'll was good a And draw a $XXX line million, billion. based years Jon pretty just that'll get revenue

the see gives So, confidence board on to putting results market the our that we're there. get while, well everything a we we're but market moving going this takes as research as that forward-looking great in us

Jon Stonehouse

around peak. $X the of the line protection almost protection remember out patent that turn And XX we so got another of crosses decade. we've XXXX, years have billion to And at

that's value. So real

Operator

Our Raymond next comes Please go Sandler. question Piper with from ahead. Chris

UnidentifiedAnalyst

volunteers. are and this color experiments and the I preclinical This signal. is completed chronic the on guys XXXXX Nicole how models question. to have chronic then where Chris. for just program, to morning. around been dose guess you maybe for guess, that the I a point? know healthy And the toxic observe any translates taking clarify, at Good evaluate dose you I higher Maybe to around just going just Thanks [ph] the toxic

Helen Thackray

Yeah. Good morning.

take to those going reverse order. I'll in So

a program, complete that had we expect of toxic chronic and to later terms toxic, still ongoing don’t the it's year. In the until in chronic we

need volunteers that the In do and well patients and At that information P.A.N.H. clinical greater terms end, assess into compliment to we outcomes, and is information further translates that we milligrams we know pathway healthy of to where the around and we'll inhibitions. is then patient we as and what our dose XXX can how the so inhibited we that trial what really, XX% dose. into go than translating confirm as to the at see [indiscernible] effect, escalating clinical from with that to that

Jon Stonehouse

at do end it's do So think dose Nicole, I And behind day, about whole in we we have the of the safe what today? But humans. and trial. effective all one see that's the a that that's point

Helen Thackray

headwinds [indiscernible] for were I guess there where with situation unanticipated lack that then helping the it. know really provide ORLADEYO. Got to funding quick, the of some I does external patients stand of quarter And currently? from just the on some charities, last

Charlie Gayer

has stabilized. The situation

So or quarter but did for quarter. Those year, product on we the to rest having first patients since on drop in free stabilized. for having the situation product stay more we the has patients back it free to of are to have not losing long-term that first now, put the this

Anthony Doyle

Yeah, think go Charlie great plus said think, they're paid traction converting making was as to he my at to despite and down. is or that's and his it's one pre-product that that in expectation, and having and down Charlie XX% to for going continue made to traction it from it's team, XX% I just big I as well great now patients

Operator

comes Cowen. Ku with question Cowen Please - Co. & Stacy from ahead. next Our TD go

Stacy Ku

our taking Thanks so much questions. for

have We follow-ups. few a

earlier. I there. the program? you've range get study, So discussed first, the regarding in development profile in the this sense of And for potential any to willing from just to regarding the potential PNH it their then and but global a the year, stop details some next know FDA provide safety or this additional And question doses of your cohort, next natural the was XXXXX a for

of our kind on are pipeline. So the questions those

the but Takeda in Salesforce, patients? and past, expanding the just exactly Thanks that so you've, sizing discussed the even competitors think about about other of treat clinicians talk communities then regarding size not those you in and potential relative to efforts ORLADEYO, only much. the And versus QX. Could not I that know you really like increasing the maybe

Jon Stonehouse

to XXXXX, Helen, and the can you take the want So Charlie, you take salesforce.

Helen Thackray

Yeah.

we're we So, mostly that own for that the initiation. can healthy are the XXXXX, those and trial PK from XXX our order purposes, for is confirm level the need is in patient that that We'll trial, milligrams, with once to our dose dose assess dose final we pivotal adding PK so model. the have volunteer that entire the that data

And so why adding we're level. that's that dose

terms PNH, in doses looking in and we're that doses be In of that looking at efficacy activity. we're we'll and trying that in to milligrams also to state. range in then, We're the dosing then of we're -- more clinical the we're but outcomes looking the we'll LCH. multiple like at in starting complement for importantly, for the outcomes. critical looking PNH the And We're population trial, for there. up that for for from hemoglobin looking assess, at for disease safety, XX be in setting, is and looking be What and

Jon Stonehouse

just it of sense for get about do you might how the sense roughly we safety, the how good short, be the talk of Helen, to follow And And a get to study. in least to to need many at those a and short we this that. patients need think patients study long that do

Helen Thackray

Yeah.

one and assess complement We to study. reasons with patients of small patients a need in that's that's a PNH. many So don't the inhibitor

doing will complement escalating is information. outcomes clinical within we individual be and and each that dose patient's their that and system and be own on patients with escalate affected dose information giving that us one how can will then You

many So patients, not very trial. small

up information, we'll as the dose well. In be safety at that as terms looking of we

to doses. safety an And so ability the patient, of range have, observe again, across we'll the individual

Jon Stonehouse

to patients And three roughly. XX months, patients months, six XX

Helen Thackray

outcome. four first Yeah. It's weeks pretty and it's to to small XX have a

Charlie Gayer

we exact our people our And thing at we people midpoint did isn’t then in territories. year, the teams few the and double that regions. the is that the did of on but sizing sales, the sales I've number, what the a beginning add of The the biggest between and before of said is XX XX number right

regional to teams and So it more time key regional directors with gave the customers. with our managers, spend

our potential prescribers force, at we When the sales is we out terms build number HAE in look market there. the of. one thing

rep. on And so for workload sales basis we it build a each

can team the doing. what at competition's we very they that efficient, And look do be comfortably our we So to best but can what also think decides we them. tell

Jon Stonehouse

BioCryst, want not they might so rep, every it's Charlie, just just from is that. see that docs talk And right? the and from hear about we team What whole the to week somebody you

Charlie Gayer

So a simultaneously, we access field. have is, market have, team do in out the we what we

we've patients, got up And our services patient So, a work that the practices. but built that medical medical they of team working expanded side, team. with course, out with closely physicians. educate excellent so We've our there, to also we've very team then, on

and get we most the at we So, look package that the feedback they're seeing as we do whole frequently. our research, BioCryst people

Stacy Ku

Very helpful. Thank you.

Operator

Abrahams Our RBC Please comes Brian ahead. question go with next from

Unidentified Analyst

everyone. Hi, is This again good on on Brian. quarter. Nevin [ph] a Congrats for

if questions couple guys pay you patients regards have confer education about about drug the in a well. of future you the in of And could of net on trends free some simplification the calls? recovery are some talk to speak taking to efforts as there efforts and you the mentioned patient of the Can to the to paperwork gross some that's I quarters and then the some of to previous also, that drug. into quarter So

Charlie Gayer

Yeah. Sure.

are with place from made the the get working we've where conversion market, is to XX% complete number the progress the the to a portion drug and one customers is insured our paperwork. the little business, is the free of most which over thing, pay making you're all within that sure drug, largest to alluding as we On commercially

whole means changing is really comprehensive anyone more success new as on complete. patient the and the getting putting free If letter of in on and got focused start we're providers helping form and who in complete approve over has medical appeal, paid is background necessity, been the more justification. mind and drug We've going lab is coming critical test. likely back got We've educate to upfront, claim. to moved So and and the Likewise, prescription is much what healthcare for in get insures more insurer all seeing a is people that clinical that and the history their more we the a family that the product. this doing our to particular, more team in,

On the goes part to quarter the that's what down where happens to gross gross net, a net bit. of first a revenue in

One our normalizes factors up is our in of then commercial that the those happens their The exhausted the hit in where with patients rest maximums for that point we take QX it biggest QX of and year. in are side many program. and to assistance on co-payment get the out-of-pocket of

gross in going ever it QX to was for be bad the to rest then it's of net as the as quarters. and normalizes So

Jon Stonehouse

expected happen. what range QX and that that range in end of the we year in QX we was into of that exactly said come Yeah, lower XX% is had to saw maintain and we that's and what the and would XX% up that it then end thread the higher

Unidentified Analyst

And ask I rates on if the also the could Okay, patients thank drug. of you. retention were then about

dropped higher the You denominator off the by had same of number I guess patients higher the mentioned that -- were there.

any retention rates in do differences in US the those ex-US geographies? what rates regards rates what they retention and look to of -- in like the those you or so And same the seeing are and are in kind those are the

Charlie Gayer

Great question.

is we've confidence a point lot saying gets this we're of history in So and discontinuation that got this at now -- very of us consistent. is the pattern seeing what that

So very a to year. year of it after therapy XX% make when a the then a on starts we people and lose about starts patient one in them patient few US,

And we're so how are that to drop many people every on is means product, in consistent US off coming our month and as patients predict base we going growing. market number can is what to the a getting of

providers people pattern the but proportion rate and actually the their down. of So just has the HA Europe overall generally on education. may patients a care when to and providing been in retention better seeing of tend keeps health just has Ex-US, think focused have larger treatment discontinue that same discontinuation we the lot of absolute to with do our centers rate we're very where as a going you better base are be

they few bumps then key months the is and very panic if drop now. that those patients know therapy what -- they that's this, to hit and to retention expect is and therapy Overall they pattern first that in we've few expectations don't of we're on that any setting and with effective so what they seen got don't think -- we've I we're has very stable the off seeing been that and focused

Operator

question Please Jon next Wolleben from comes ahead. Our JMP Securities. with go

Jon Wolleben

Good taking for questions. morning. Thanks the

we talk status a and wondering steady stable, then Charlie why two you of XQ, between revenues with dynamic, if for those should the free the be guidance the goal you're about the don’t drug year that seeing little happen half XQ, mentioned think drug to the could seems or and On year you get most a second free steady that points? like expect should I'm with bit on drug. when XX% half of you to at least less but in free movement the any patient back steady revenue on

Charlie Gayer

Sure, the of we sales It'll progress what's getting our the in year in half continued second kind I the people going pay yeah, to is to yeah, growth the so of just drive the make expect year. to of second but half growth question contribute, really think the patient second incremental drug.

going what to but as XX% the this get to as focused few on far expect the there, early therapy we're you do months get so As us years already getting there. or last new plus paid be the few time when that to we seeing that get starting everyone confidence to over to that in really we're are rate better, to a an it's XX% take to on going gives able we're is and patient

this sales patients So difference. to to with and the providers team services team, access work team all what's our patient about focus, making our market working is educate together of that and team it's that our the payers to I think continue healthcare

Jon Wolleben

ex-US or an little if And going if or be this Wondering to expect revenue tipping going to the countries going it's there's things certain and this should well. know ex-US. driving a you see mentioned bit you consistent point expansion maybe there to to acceleration are geographic any higher if the well about going most grind is contributing be point we be

Charlie Gayer

seeing growth. or expect wouldn't I same of point really patient the a Yeah pattern tipping We're acceleration.

we've US As add perspective. a one talked patient to revenue it four patients to about takes just a up ex-US from good

will keep we'll steady patient countries. one keep We so at number the is growth the adding thing

expect next in Europe. we way year to of two launch So our

So Italy Benelux. and Spain like countries and

our a big So steady those have but to revenue wouldn't I inflection we'll growth. point continued additions stream, expect

Jon Wolleben

I Charlie. color. the appreciate Thanks

Operator

question next Oppenheimer from Please & Co. Justin go Our ahead. with Kim comes

Justin Kim

high versus And then could nature prescribers. patients prophylaxis of growths mix due bar those update volume on added question. clinical for for whether these think a coming you're you inform approved and alternative required, or then just whether commercial of first Hi. maybe taking Thanks from Good us being the Charlie, again bar to morning. how may and well the our on inhibition terms the as perhaps commercial, think I prescribers the the slow might one just experience Thanks. are you lower of front there? PNH, naïve additional observing, data a Maybe just be to you results those about a the quick discuss just being in or can pathway for competitive

Helen Thackray

Sure.

to So is that understand PNH gets question, on to the we next us efficacy. the need what dose

We're clinical number getting understand by an inhibition outcomes is pathway patients, looking of small then that and that fairly opportunity looking clinical in both the dose effective to a rigorous we're outcomes. at what both. need to is and translate see demonstrate quickly safe know measured and with complement the that because the for So a that PNH is we we we're whether the excellent a to achieving to and dose on that effect that's conference

drug pivotal dose and and other And sort achieve PNH expect would we're as the take treating translate dosing. looking as or looking other we -- the reminder, to from one and one and and what field seeing forward. complement IGN We of we're that's a that daily efficacy dose the that at we're diseases that then in into we looking of assign, we're that better diseases. we're differentiated to and as opportunity would a to would safety with then understand We're for take inhibition for good

Jon Stonehouse

that's And inhibitors. the pathway with others in what have done alternative field

is this patient patterns. again the ground. Justin new consistent a mix, prescriber on story is then and So And the

tell we're recently the the least on So a product other other naive. still patients completely we products and coming about are of we're XX% not can prophylaxis from or prophylaxis at best XX%

see So that consistency. it's to great

a seeing prescribers the get less that other half larger we ones consistent the number talked then we're quarter very new added. great little then from what's than every being group of And a a And on prescriber the prescriptions mix, about, is ORLADEYO I've doctors XXX top get more physicians. of treat of that of of XX% our the half market and little those we from than about who

then to within go market continue existing and prescribers. we broader So prescriber deeper

Operator

instructions] Needham ahead. next Co. Serge question & Please with Belanger [Operator comes go Our from

Serge Belanger

A at morning. have asked Hey, point. questions this been of lot good

within and the additional maybe from from maybe recently, of talk So you've enrolment -- couple that was ORLADEYO attending meeting, Summit start any awareness whether a of told you've just the level you around met that there quick the in me HAEA about experienced program. the the patients seen tailwind let

Charlie Gayer

an first had launched all, there. earlier, time our there attending patient Serge launched, Yeah, traffic said great ORLADEYO Jon little had says, did this A as since conversations what was oh, frustrating, big -- and always but a both and patient of it's so we we our two a of had we've we a it's booths, booth. lot through We lot a presence booths, branded drug booth but hear a of coming unbranded did first and a and we this that.

is said, they And on ORLADEYO so know that ORLADEYO market. the and we market it's patients is all on they family great members, the left now X,XXX as knowing and

what getting and our different in may that telling is may ORLADEYO healthcare -- about patients they have we're they So conference out this just about ORLADEYO. happened be and questions this their asking providers is that questions and coming there therapy

the and getting was of see get and together see important them a if it was community definitely it just their excitement milestone really but tailwind, So great and -- it an to just was we great just it was we'll again a see meeting. to

Jon Stonehouse

and life like family an word of we changed like I ORLADEYO God, think like part and spread mouth other got certain a let that and meetings to the think It's reconnected. the number patient bunch of certain a the It they my because be came my stuff that is country, watching what why. first people reunion explain honestly state of of you it's gather thing it's the me stopped. will of people has hope and oh up I I regionally. All was COVID equal and a so a

And other patients to helpful about so too. think going talking that's when to I they're that, be

the just last dynamic there was, go meeting and you are patient quad the AI. at the piece a then well college KOLs it's different a and to as And when meeting or

us and to reinforce differentiates our a a a in other so way connect and the maybe really I in we're to up in with that harder chance it's way settings. able it's that and think And KOLs competition maybe from show and

fantastic. So was it

Operator

Our [indiscernible] question Please comes Barclays. go with next ahead. from

Unidentified Analyst

[ph] on even warrant, would Tony is or on what Day further Gena this R&D A data expect pipeline of for think new Wang. at on what this question development I to see further on XXXX, quick maybe potentially we Sorry, and assets. kind could initial

Helen Thackray

the for in and need I That we patients levels Yeah, what with that's that for we're we'll also to and think to we seeing really that looking are in safe. see looking we're straightforward XXXX be we're activity okay, clear. show. looking data looking something clinical quite in for for a that's so, manner We're outcomes quite

safety So and efficacy looking and to simple, daily we're that we're once or looking it's for fairly patients with for then is that's than what dosing. good better as available

for the which invest further point we've have decision Once making dose selected then of we the to see and and that program the been that's state pivotal trials.

update In across the pipeline. terms of R&D Day, we'll

Birmingham Here really in and we company. with co the in and of happening been what's programs we've a working things and the in number on am pleased excited within have been early discovery that I

we'll it's there. So and pipeline depths be the discussing of that some breadths

Jon Stonehouse

will and XXXX then on before. I heard new Yeah that will any double be stuff be information this of point, you've there not at

Unidentified Analyst

new it that of questions quick for the lot got then guidance switching. anything or either on very one Okay, I of lead helpful guess another sales retention of XXX has could rate Is ORLADEYO exceeding already. patients kind to been in and launch a terms patients and or there there

Jon Stonehouse

confident number on should that's think really the in what XXX year. We're seeing, this you and based expect I for we're what

same the XXX to us paid XXX. over So then getting what consistent and patient the to US get patient I therapy that's growth, incremental that growth described the to pattern retention earlier of outside about the and progress will that on patients continued get us

Operator

go Our final question comes Maury Jefferies. from with Raycroft Please ahead.

Unidentified Analyst

Hi. is Thanks Maury. quarter. Good questions. good a the morning. Congrats guess is Young question for growth. for QX on on This our our revenue taking [ph] I first

the from be affected How force going last revenue saying and of about effect this that a bit growth is rate July for year the saw relative You're the there ordering was growth From confounding holiday steady. year? year think we to QX should factor the more that QX. of of the rest we

Charlie Gayer

all the process. QX coming jump out as QX QX QX the in and by a QX is So patient growth factors big reauthorization revenue because driven be will not of the as but also

Anthony in about that million bit should as in bit to his a more less So for a we described $XX.X QX to little than average get the the QX XXX. little -- in comments,

For so on July the Tuesday yeah was July this XX year. XX, a

day and two everyone that built a that we that specially shipments June and our we We reminder into part source that of a into have our saw year was year. in as a this sole so there the So came plan was just and for US or pharmacy. of expectation happened last

So of this like around demand individual see forward, day going usually you patient Xth patients pull and times two bit of July lot of there will of or and just a shipments. all holiday but is based it's a a on away so the are little a for that

Unidentified Analyst

ORLADEYO insights patients into world, of therapy, thought successfully if Maybe you quick any we one about sharing you're on just CX see. profile, I are rate retention year this [indiscernible]. normal I'm how normal anything right. some data if just the CX wondering in patients managing a how like with many the see that's on them normal you're CX how seeing real earlier and on patients, and

Charlie Gayer

get other poster, patients. shared [indiscernible] that proportion you the than Yeah terms business. in seen the But of do one haven’t we normal of we our on the what number saw

for Type are looked and ORLADEYO so reported that clear patient in we're is products reduction It's number struggled a So I prophylaxis seeing been all seeing work have them of isn’t as therapies Type and attack they’ve patients These consistent attack really patients. and cut is are rates. lot and the for normal their them seeing that what as for and rates years. X of -- think diagnosis we're CX helping a really X who so

Type And CX X as patients. Type from we with and we're retention normal a retention about with patients good just are X as perspective, seeing

we on what very patients. what And seeing future, in data us the these from is so, you more now pleased we're can can but this help expect in right we're

Unidentified Analyst

much. so Congrats Thanks it. Got again.

Operator

This the now and for concludes that today's concluded. has conference our session you Thank with question-and-answer attending presentation.

made You out disconnect.

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.